ClinicalTrials.gg
CompletedNCT00607087PUMPUpdated Aug 31, 2010Results posted

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

A Phase 4 interventional study of Insulin glulisine and Insulin lispro in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 12 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-31.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
289
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 1.

Enrollment
3rd of 25
289 · median 72
Started
2008
the only one that year
Phase 4
14 of 26
none open now
Registered
11th of 26
by date
Lead sponsor
15 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2008, is one of 14 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.

Main Secondary objectives:

To compare insulin glulisine, insulin aspart and insulin lispro on:

  • Unexplained hyperglycemia
  • Infusion set occlusion
  • Hypoglycemic episodes,7-point blood glucose profiles
  • Episodes of significant ketosis and/or risk level for impending diabetic ketoacidosis
  • Time to change the infusion set
  • HbA1c (Glycosylated hemoglobin)
  • Overall safety: incidence of adverse events
Read the detailed description

The maximal duration of the study participation for patients was 41 weeks and one day, split in:

  • a 2-week screening period,
  • a 39-week treatment period: 3 treatment periods of 13 weeks with a crossover alternative regimen, including a dose adjustment period of 1 week at the beginning of each period (sequence1: insulin glulisine, then insulin aspart, then insulin lispro; sequence2: insulin aspart, then insulin lispro, then insulin glulisine; sequence 3: insulin lispro, then insulin glulisine, then insulin aspart)
  • and a follow-up period of 24 hours.
03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetic subjects
  • Treated with insulin for at least 2 years and by CSII for at least 6 months
  • Using the same insulin (insulin glulisine, insulin aspart or insulin lispro) in CSII for at least 3 months with the same external pump compatible with the 3 short acting insulin analogues used in the study
  • Using the same type of infusion set (catheter and cannula) for at least 3 months
  • Performing at least 3 blood glucose controls per day
  • \< 8.5%
  • (BMI) \< 35 kg/m²
  • Ability and willingness to perform blood glucose and ketone monitoring using the Sponsor-provided combined glucose and ketone meter and patient diary at home

Exclusion criteria

Exclusion Criteria:

  • Diabetes other than Type 1
  • Total daily dose of insulin greater than 90 U/day
  • Using an insulin pump requiring pre-filled cartridges
  • History of infection at infusion site requiring a drainage in the last 3 months
  • History of severe episodes of ketosis requiring hospitalization in the last 6 months
  • Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study. An ophthalmoscopic examination should have been performed in the 2 years prior to study entry
  • Pregnancy (women of must have a negative pregnancy test at study entry and a medically approved method) or breastfeeding
  • Treatment with systemic or medication known to influence insulin sensitivity in the 3 months prior to visit 1
  • Treatment with antidiabetic drug other than insulin in the 3 months prior to visit 1
  • Likelihood of requiring treatments during the study which are not permitted
  • Treatment with an product in the 30 days prior to visit 1
  • History of sensitivity to the study drugs or to drugs with a similar chemical structure
  • Presence of any condition (medical, including abnormal laboratory test, psychological, social or geographical) actual or anticipated that the Investigator feels would compromise the patient safety or limit his/her successful participation in the study
  • Night shift workers
  • Impaired renal function as shown by serum creatinine ≥1.5 mg/dL (133 μmol/L) or ≥1.4 mg/dL (124 μmol/L) in men and women, respectively
  • Impaired hepatic function as shown by (ALT) and/or Aspart aminotransferase (AST) greater than three times the )
  • Alcohol or drug abuse in the last year
  • Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    sequence 1

    sequence 1: insulin glulisine / insulin aspart / insulin lispro.

    Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart

  • Experimental
    Sequence 2

    Sequence 2: insulin aspart / insulin lispro / insulin glulisine

    Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart

  • Experimental
    Sequence 3

    Sequence 3: insulin lispro / insulin glulisine / insulin aspart

    Drug: Insulin glulisine · Drug: Insulin lispro · Drug: Insulin aspart

Interventions

  • 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

  • 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

  • 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion

    Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

    Time frame: over 13 weeks of each treatment period

Secondary outcomes

  1. Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion

    Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

    Time frame: over 13 weeks of each treatment period

  2. Percentage of Patients With at Least One Unexplained Hyperglycemia

    Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.

    Time frame: over 13 weeks of each treatment period

  3. Monthly Rate of Unexplained Hyperglycemia

    Time frame: over 13 weeks of each treatment period

  4. Percentage of Patients With at Least One Confirmed Infusion Set Occlusion

    Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

    Time frame: over 13 weeks of each treatment period

  5. Monthly Rate of Confirmed Infusion Set Occlusion

    Time frame: over 13 weeks of each treatment period

  6. Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis

    Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l

    Time frame: over 13 weeks of each treatment period

  7. Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis

    Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l

    Time frame: over 13 weeks of each treatment period

  8. Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year

    Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.

    Time frame: over 13 weeks of each treatment period

  9. Rate of Severe Symptomatic Hypoglycemia Per Patient-year

    Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following: * the event was associated with a measured blood glucose level below 36 mg/dL * or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.

    Time frame: over 13 weeks of each treatment period

  10. Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year

    Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.

    Time frame: over 13 weeks of each treatment period

  11. Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site

    Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment. Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment. Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection. Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.

    Time frame: over 13 weeks of each treatment period

  12. Time Interval Between Infusion Set Changes: All Changes

    Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). "All changes" include all the changes whatever the reason such as routine or requested by occurrence of events.

    Time frame: over 13 weeks of each treatment period

  13. Time Interval Between Infusion Set Changes in Routine

    Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). Changes in routine correspond to interval between changes according to patient use.

    Time frame: over 13 weeks of each treatment period

  14. Glycosylated Hemoglobin: HbA1c

    Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%

    Time frame: over 13 weeks of each treatment period

  15. Total Daily Basal Insulin Infusion

    dose of the basal insulin regimen administered throughout the 24-hour period

    Time frame: over 13 weeks of each treatment period

  16. Total Daily Bolus Insulin Dose

    dose of every increment administered for example before meals

    Time frame: over 13 weeks of each treatment period

07

Results

Posted Jul 30, 2010

Participant flow

Multicenter study: 44 active centers from 12 countries in Europe, USA and Asia Pacific region. Study Initiation date: January 8, 2008, Study Completion Date: June 15, 2009.

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3
Started999594
Completed848484
Not completed151110
Withdrew: Withdrawal by subject944
Withdrew: Adverse event323
Withdrew: Other reason152
Withdrew: Poor compliance to protocol101
Withdrew: Lost to follow-up100
Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3
Started999594
Completed878989
Not completed1265
Withdrew: Withdrawal by subject723
Withdrew: Adverse event300
Withdrew: Poor compliance to protocol100
Withdrew: Lost to follow-up100
Withdrew: Other reason042
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3
Started878989
Completed868684
Not completed135
Withdrew: Withdrawal by subject011
Withdrew: Other reason110
Withdrew: Adverse event013
Withdrew: Poor compliance to protocol001
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3
Started868684
Completed848484
Not completed220
Withdrew: Withdrawal by subject210
Withdrew: Adverse event010

Outcome measures

PrimaryPercentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion

Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

Time frame:
over 13 weeks of each treatment period
Reported as:
Number · percentage of patients
Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion
percentage of patientsInsulin GlulisineInsulin AspartInsulin Lispro
Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion68.4 (62.7 to 74.1)62.1 (56.2 to 68.1)61.3 (55.4 to 67.3)
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · McNemar · p = 0.039 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = 0.031 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025.)
SecondaryMonthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion

Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason. Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events per patient per month
Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion
events per patient per monthInsulin GlulisineInsulin AspartInsulin Lispro
Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion2.02 ± 0.151.32 ± 0.151.54 ± 0.15
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryPercentage of Patients With at Least One Unexplained Hyperglycemia

Unexplained hyperglycemia defined as blood glucose value above 300 mg/dL (16.7 mmol/L) with no apparent medical dietary, insulin dosage or pump failure reason.

Time frame:
over 13 weeks of each treatment period
Reported as:
Number · percentage of patients
Percentage of Patients With at Least One Unexplained Hyperglycemia
percentage of patientsInsulin GlulisineInsulin AspartInsulin Lispro
Percentage of Patients With at Least One Unexplained Hyperglycemia61.3 (55.4 to 67.3)55.9 (49.8 to 61.9)56.3 (50.2 to 62.3)
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · McNemar · p = 0.080 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = 0.107 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryMonthly Rate of Unexplained Hyperglycemia
Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events per patient per month
Monthly Rate of Unexplained Hyperglycemia
events per patient per monthInsulin GlulisineInsulin AspartInsulin Lispro
Monthly Rate of Unexplained Hyperglycemia1.61 ± 0.131.04 ± 0.131.23 ± 0.13
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryPercentage of Patients With at Least One Confirmed Infusion Set Occlusion

Pump infusion set occlusion defined by at least one of the following items: * pump occlusion alarm, * patient observation of an occlusion, spontaneously or because of elevated blood glucose value.

Time frame:
over 13 weeks of each treatment period
Reported as:
Number · percentage of patients
Percentage of Patients With at Least One Confirmed Infusion Set Occlusion
percentage of patientsInsulin GlulisineInsulin AspartInsulin Lispro
Percentage of Patients With at Least One Confirmed Infusion Set Occlusion32.8 (27.1 to 38.6)27.0 (21.5 to 32.4)27.0 (21.5 to 32.4)
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · McNemar · p = 0.079 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = 0.063 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryMonthly Rate of Confirmed Infusion Set Occlusion
Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events per patient per month
Monthly Rate of Confirmed Infusion Set Occlusion
events per patient per monthInsulin GlulisineInsulin AspartInsulin Lispro
Monthly Rate of Confirmed Infusion Set Occlusion0.41 ± 0.060.28 ± 0.060.31 ± 0.06
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = 0.015 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = 0.073 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryPercentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis

Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l

Time frame:
over 13 weeks of each treatment period
Reported as:
Number · percentage of patients
Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis
percentage of patientsInsulin GlulisineInsulin AspartInsulin Lispro
Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis17.6 (12.9 to 22.2)10.9 (7.1 to 14.8)11.7 (7.8 to 15.7)
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · McNemar · p = 0.017 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = 0.032 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryMonthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis

Diabetic ketoacidosis (DKA) is preceded by an increase in ketone production, resulting in blood ketone value increase (hyperketonemia) and later in ketone urine value (hyperketonuria). Significant hyperketonemia and risk level for impending diabetic ketoacidosis (DKA) are reported respectively as a blood ketone value from 0.6 to 1.5 mmol/L and \>1.5 mmol/l

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events per patient per month
Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis
events per patient per monthInsulin GlulisineInsulin AspartInsulin Lispro
Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis0.14 ± 0.430.06 ± 0.220.06 ± 0.18
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = 0.009 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = 0.019 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryRate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year

Symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events in patient-year
Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year
events in patient-yearInsulin GlulisineInsulin AspartInsulin Lispro
Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year73.88 ± 4.7465.06 ± 4.7462.74 ± 4.74
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = 0.008 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryRate of Severe Symptomatic Hypoglycemia Per Patient-year

Severe symptomatic hypoglycemia is defined as an event with clinical symptoms that are considered to results from hypoglycemia in which the patient required assistance of another person and one of the following: * the event was associated with a measured blood glucose level below 36 mg/dL * or event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events in patient-year
Rate of Severe Symptomatic Hypoglycemia Per Patient-year
events in patient-yearInsulin GlulisineInsulin AspartInsulin Lispro
Rate of Severe Symptomatic Hypoglycemia Per Patient-year1.63 ± 0.351.39 ± 0.351.07 ± 0.35
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = 0.563 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = 0.186 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryRate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year

Nocturnal Symptomatic hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia (confirmed or not by a glucose measurement) and associated with prompt recovery after oral carbohydrate administration which occurs while the patient is asleep, after bedtime and before getting up in the morning.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · events in patient-year
Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year
events in patient-yearInsulin GlulisineInsulin AspartInsulin Lispro
Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year12.80 ± 0.959.66 ± 0.959.48 ± 0.95
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · Mixed Models Analysis · p = <0.001 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryPatients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site

Infection: local reaction at the infusion site requiring local or systemic antibiotherapy, or local drainage as per Investigator judgment. Site inflammation or erythema: local reaction at the infusion site with no need for local or systemic antibiotherapy as per Investigator judgment. Pruritis at injection site: presence of pruritis at the infusion site without any symptom of inflammation or erythema and/or infection. Isolated pain at injection site: presence of pain at the infusion site without any symptom of inflammation or erythema and/or infection.

Time frame:
over 13 weeks of each treatment period
Reported as:
Number · patients
Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site
patientsInsulin GlulisineInsulin AspartInsulin Lispro
Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site110110107
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · McNemar · p = 1.000 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
  • Insulin Glulisine vs Insulin Lispro · McNemar · p = 0.701 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)
SecondaryTime Interval Between Infusion Set Changes: All Changes

Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). "All changes" include all the changes whatever the reason such as routine or requested by occurrence of events.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · hours
Time Interval Between Infusion Set Changes: All Changes
hoursInsulin GlulisineInsulin AspartInsulin Lispro
Time Interval Between Infusion Set Changes: All Changes69.1 ± 20.7069.44 ± 19.2269.98 ± 21.64
SecondaryTime Interval Between Infusion Set Changes in Routine

Patients treated with insulin pump have to change their infusion set regularly (i.e.change was recommended every 48h). The patients were asked to report any change of their infusion set and the reason for change (routine basis or because of occurrence of a specific event such as occlusion, unexplained hyperglycemia or adverse event). Changes in routine correspond to interval between changes according to patient use.

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · hours
Time Interval Between Infusion Set Changes in Routine
hoursInsulin GlulisineInsulin AspartInsulin Lispro
Time Interval Between Infusion Set Changes in Routine70.72 ± 21.4771.00 ± 20.6871.07 ± 21.65
SecondaryGlycosylated Hemoglobin: HbA1c

Glycolysated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow-up in diabetic patients. This parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · percentage
Glycosylated Hemoglobin: HbA1c
percentageInsulin GlulisineInsulin AspartInsulin Lispro
First week (week 1) (n=253, n=254, n=255)7.31 ± 0.717.33 ± 0.717.28 ± 0.71
Last week (week 13) (n=252, n=255, n=251)7.32 ± 0.037.25 ± 0.037.33 ± 0.03
Statistical analysis
  • Insulin Glulisine vs Insulin Aspart · ANCOVA · p = 0.078 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)ANCOVA adjusted on HbA1c value at the start of the first period
  • Insulin Glulisine vs Insulin Lispro · ANCOVA · p = 0.938 (The p-value is adjusted for multiple comparisons. Each comparison is performed at the alpha level=2.5% (instead of 5%). Consequently a difference between 2 treatments is statistically significant if the corresponding p-value is \<0.025)ANCOVA adjusted on HbA1c level at the start of the first period
SecondaryTotal Daily Basal Insulin Infusion

dose of the basal insulin regimen administered throughout the 24-hour period

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · Units
Total Daily Basal Insulin Infusion
UnitsInsulin GlulisineInsulin AspartInsulin Lispro
First week (week 1) (n=251, n=249, n=250)20.83 ± 9.0520.93 ± 9.4520.85 ± 9.16
Last week (week 13) (n=251, n=249, n=251)20.86 ± 9.2420.81 ± 9.7321.11 ± 9.38
SecondaryTotal Daily Bolus Insulin Dose

dose of every increment administered for example before meals

Time frame:
over 13 weeks of each treatment period
Reported as:
Mean · Units
Total Daily Bolus Insulin Dose
UnitsInsulin GlulisineInsulin AspartInsulin Lispro
First week (week 1) (n=249, n=247, n=250)18.63 ± 9.2218.49 ± 9.0018.40 ± 8.69
Last week (week 13) (n=248, n=244, n=249)18.58 ± 8.4918.64 ± 9.6019.19 ± 9.13

Adverse events

Collected over Adverse events are collected from the first to the last drug intake (3 periods x 13 weeks) + 1 week after the administration of the last intake i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Glulisine—29/274 (10.6%)47/274 (17.2%)
Insulin Aspart—18/266 (6.8%)24/266 (9%)
Insulin Lispro—11/269 (4.1%)30/269 (11.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventInsulin GlulisineInsulin AspartInsulin Lispro
ketosisMetabolism and nutrition disorders9/2744/2662/269
hypoglycaemic seizureMetabolism and nutrition disorders8/2743/2664/269
hypoglycaemic unconsciousnessMetabolism and nutrition disorders4/2746/2662/269
hypoglycaemiaMetabolism and nutrition disorders3/2740/2660/269
arteritis coronaryCardiac disorders0/2741/2660/269
coronary artery stenosisCardiac disorders0/2741/2660/269
myocardial infarctionCardiac disorders0/2741/2660/269
overdoseInjury, poisoning and procedural complications1/2741/2660/269
headacheNervous system disorders0/2741/2660/269
hypoglycaemic comaNervous system disorders0/2741/2660/269
Most frequent other events
Most frequent other events
EventInsulin GlulisineInsulin AspartInsulin Lispro
KetosisMetabolism and nutrition disorders47/27424/26630/269

Baseline characteristics

Age Continuous
Age Continuous(years)Sequence 1Sequence 2Sequence 3Total
Mean43.45 ± 13.7145.84 ± 13.5944.04 ± 12.8744.43 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Total
Female495448151
Male504146137
Region of Enrollment
Region of Enrollment(participants)Sequence 1Sequence 2Sequence 3Total
United States22212164
France891027
Hungary44614
Spain1191030
Austria79824
Australia44311
Israel11111032
Netherlands88723
United Kingdom54413
Italy97723
Sweden98724
Korea, Republic of1113
Previous insulin at study entry
Previous insulin at study entry(participants)Sequence 1Sequence 2Sequence 3Total
Insulin glulisine4228
Insulin aspart324342117
Insulin lispro634950162
Duration of treatment with previous insulin at study entry
Duration of treatment with previous insulin at study entry(years)Sequence 1Sequence 2Sequence 3Total
Mean4.84 ± 3.584.37 ± 3.054.79 ± 3.004.67 ± 3.22
Duration of treatment with insulin at study entry
Duration of treatment with insulin at study entry(years)Sequence 1Sequence 2Sequence 3Total
Mean22.39 ± 13.5323.07 ± 13.3322.75 ± 11.0822.73 ± 12.67
Total daily bolus insulin dose
Total daily bolus insulin dose(Units)Sequence 1Sequence 2Sequence 3Total
Mean19.61 ± 9.4018.58 ± 10.3419.35 ± 7.7819.18 ± 9.22
Duration of treatment with CSII (continuous subcutaneous insulin infusion) at study entry
Duration of treatment with CSII (continuous subcutaneous insulin infusion) at study entry(years)Sequence 1Sequence 2Sequence 3Total
Mean5.99 ± 4.835.52 ± 5.276.31 ± 4.955.94 ± 5.01

4 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    PE Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011 Jun;13(6):607-14. doi: 10.1089/dia.2010.0224. Epub 2011 Apr 2. PubMed 21457066 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2008
First posted
Feb 5, 2008
Start
Jan 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jul 30, 2010
Last update
Aug 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00607087
Lead sponsor
Sanofi
First posted
Feb 5, 2008
Start date
Jan 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jul 30, 2010
Last update
Aug 31, 2010

Study contacts

Medical Affairs
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Lispro · Insulin Aspart

Start the discussion